Health Care [ 9/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205.
It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans.
In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers.
Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.79 Increased by +37.30% | -0.78 Decreased by -1.94% |
| Mar 12, 25 | -0.60 Increased by +41.18% | -0.74 Increased by +18.56% |
| Nov 6, 24 | -0.60 Increased by +20.00% | -0.74 Increased by +18.92% |
| Aug 8, 24 | -0.31 Increased by +77.37% | -0.95 Increased by +67.37% |
| May 9, 24 | -1.26 Decreased by -1.47 K% | -1.00 Decreased by -26.00% |
| Mar 14, 24 | -1.02 Decreased by -1.18 K% | -0.62 Decreased by -64.52% |
| Nov 8, 23 | -0.75 Decreased by -733.33% | -0.84 Increased by +10.71% |
| Aug 8, 23 | -1.37 Decreased by -1.04 K% | -1.06 Decreased by -29.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -52.10 M Decreased by -53.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -9.98 M Decreased by -8.85 K% | -64.55 M Decreased by -135.86% | Increased by +647.06% Increased by +102.70% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -23.97 M Decreased by -19.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 10.00 M Increased by +N/A% | -8.26 M Increased by +66.00% | Decreased by -82.56% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -33.86 M Decreased by -163.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 114.00 K Decreased by -95.61% | -27.37 M Decreased by -62.71% | Decreased by -24.01 K% Decreased by -3.61 K% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -20.00 M Decreased by -10.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -24.28 M Decreased by -10.61% | Decreased by N/A% Decreased by N/A% |